Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle. The company ...

Max Branch's seven pet cats turn his Brooklyn, New York, home into a biscuit-making factory every day, working hard at their jobs kneading away. Cat owners and cat lovers on Instagram and TikTok ...

The what, now? you may ask, reading this title. The social life of cats? Cat owners may have some doubts about this very concept. But in the last decade or so, there has been an upsurge of more ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ...

If you've ever owned or cared for cats, you know that they tend to have their unique way of doing things and their individual temperaments. Some cats are attached to your hip while others don't ...

Cytokinetics' aficamten shows strong potential in the $3B U.S. oHCM market, despite competition from Bristol Myers’ Camzyos. Stifel sets a $80 price target, highlighting catalysts expected over ...

Last year, cat owner Chelsea, of Denver, Colorado, noticed that her "old lady cat" named Hari appeared to be slowing down and was struggling to keep up with her feline siblings. Hari was rescued ...